Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label QX005N in adult chronic rhinosinusitis with nasal polyps
ChiCTR2300076861Phase 2Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QX005N in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Beijing Tongren Hospital. Primary endpoint: Adverse Events Related to QX005N Injection. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
QX005N
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on ChiCTR2300076861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076861.